Vaccine News

Vaccine news brought to you by Precision Vaccinations.

Nov 2, 2025 • 4:15 am CST
US CDC 2025

The Nipah virus, one of the world's deadliest viral pathogens, can lead to a variety of clinical outcomes in humans, ranging from asymptomatic infections to severe respiratory illnesses and fatal encephalitis, says the World Health Organization (WHO).

The WHO estimates its case fatality rate for this virus is between 40% and 75%.

During 2025, related fatalities were confirmed in Bangladesh and India. 

Unfortunately, no preventive vaccines are available for this virus that is transmitted to humans from bats or pigs as of November 2, 2025.

Recently, a new defense strategy against the Nipah virus has been developed in collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), the University of Oxford, and the Serum Institute of India Pvt Ltd., the world's largest vaccine manufacturer.

Their goal is to create the largest investigational-ready reserve of a Nipah virus vaccine candidate.

CEPI funding of up to $7.3 million will support SII for process development and manufacturing of the University of Oxford's ChAdOx1 NipahB vaccine candidate.

Dr. Umesh Shaligram, Executive Director, Serum Institute of India, commented in a press release in October 2025, "The collaboration with CEPI and the University of Oxford to develop and manufacture an investigational reserve of the ChAdOx-Nipah vaccine candidate marks a significant step forward in our pandemic preparedness efforts."

"Leveraging our proven manufacturing capabilities and past success with the ChAdOx platform, we are proud to help establish the world's largest investigational reserve against the Nipah virus—one of the deadliest pathogens known. Our aim is to ensure that life-saving doses reach those most in need, particularly across the Global South."

SII will manufacture doses for use in a Phase II clinical trial in a Nipah-affected country, and create an investigational reserve of up to 100,000 doses, which could be deployed under emergency use during a future Nipah virus outbreak, helping to generate critical data and potentially halt an epidemic in its tracks.

SII will supply the Phase II doses to the University of Oxford, which is conducting the clinical trials. These mid-stage trials are set to be the first Phase II trials for a Nipah virus vaccine candidate anywhere in the world.

Earlier in 2025, the CEPI and the U.S. Department of Defense launched a joint effort against Nipah virus treatment and prevention.

Oct 28, 2025 • 4:46 am CDT
Google Maps 2025

The Czech Republic (Czechia) is currently experiencing what may be the largest hepatitis A epidemic in the last 46 years, as reported by Ivana Lesková from MF DNES.

Since the arrival of the virus from Slovakia in April 2024, the State Institute of Health has documented 2,141 cases of hepatitis A and 26 related fatalities, including ten in Prague.

As of October 28, 2025, the Institute of Health has noted a significant increase in demand for hepatitis A vaccinations.

This year alone, more than 127,000 doses have been administered—almost double the total from last year. Due to this surge in demand, there are currently shortages of the vaccine.

However, the State Institute for Drug Control has announced to the local media that extraordinary vaccine shipments are on their way to the Czech Republic.

This vaccine shortage extends the HepA risk to over 20 million international travelers who may visit Czechia this year.

Currently, the U.S. CDC recommends that unvaccinated travelers aged 1 year or older visiting Czechia in 2025 speak with a healthcare provider about immunization options. 

For international travelers who are allergic to a vaccine component, they should receive a single dose of immune globulin, which provides adequate protection for up to 2 months, depending on the dosage given.

Unvaccinated travelers who are over 40 years old, are immunocompromised, or have chronic medical conditions planning to depart for a risk area in less than 2 weeks should get the initial dose of vaccine and, at the same appointment, receive immune globulin, says the CDC.

Oct 27, 2025 • 2:53 pm CDT
PAHO October 2025

According to the Pan American Health Organization (PAHO) mosquito-transmitted disease dashboard, Mexico has reported over 109,771 dengue fever cases in 2025.

As of October 27, 2025, there have been 48 dengue-related fatalities confirmed this year.

Last year, Mexico reported 558,846 dengue cases and 478 related fatalities.

Specifically, during epidemiological week 39, 17 countries reported the circulation of dengue in the Region of the Americas: Brazil, Costa Rica, El Salvador, Mexico, and Panama. As of this week, the subregion exhibits a decrease of 77% compared to the same week in 2024

Several of these locations reported the the simultaneous circulation of DENV-1, DENV-2, DENV-3, and DENV-4 virus subtypes.

To Mexico's north, the Texas DSHS Arbovirus Activity Report Week #42 disclosed 45 dengue cases this year.

In 2024, Texas reported 143 dengue cases and one related fatality.

In Cameron County, one locally transmitted dengue case was confirmed. 

Without access to dengue vaccines, Texas says, since Aedes mosquitoes usually bite people during the day, especially during early morning hours before daybreak and in the late afternoon before dark, when they are most active, use a mosquito repellent containing "DEET" on exposed skin to prevent infections.

Oct 27, 2025 • 4:01 am CDT
US Dept State October 2025

The travel advisory for the Republic of Mali, a landlocked country in West Africa, has been elevated to Level 4 status by the U.S. Department of State.

As of October 24, 2025, the State Department stated U.S. residents 'should not visit Mali for any reason.'

Furthermore, the U.S. government cannot provide routine or emergency services to U.S. citizens outside Bamako due to safety risks.

Have a plan to leave in an emergency that does not depend on U.S. government help, and enroll in the Smart Traveler Enrollment Program to receive digital alerts from the U.S. embassy. Enrolling helps the U.S. embassy contact you or your emergency contact in an emergency.

About 200,000 international travelers visit Mali annually.

From a health perspective, medical services for routine and emergency procedures are limited in Mali. Health facilities are available in major cities. It may be harder to find adequate health care in rural areas.

The U.S. CDC previously issued Level 1: Practice Usual Precautions for Mali regarding dengue and measles outbreaks. In addition to these diseases, the CDC recommends vaccination against yellow fever, typhoid, polio, and malaria medications when visiting Mali in 2025.

These vaccines and medications are offered at travel pharmacies.

Oct 27, 2025 • 3:37 am CDT
Israel MOH October 26, 2025

Israel's Health Ministry has reported the death of an unvaccinated toddler from a measles infection. The child died due to complications related to the virus.

As of October 26, 2025, this child marks the eighth death recorded since the measles outbreak began, with all cases involving infants who did not have any underlying medical conditions and were unvaccinated.

During 2025, there have been 1,778 measles cases and 574 hospitalizations. 

The Ministry reported in a press release that the current measles outbreak areas include Jerusalem, Beit Shemesh, Bnei Brak, Harish, Modi'in Illit, Nazareth Illit, Kiryat Gat, Ashdod, Safed, Netivot, and the Mateh Binyamin Regional Council.

In these areas, people can visit family care centers and health maintenance organizations, and vaccinations are available without an appointment.

The Ministry advises unvaccinated individuals and parents of infants who have received one dose of the vaccine to avoid participating in large gatherings in outbreak areas due to the risk of infection.

As a result of the Ministry's efforts to increase vaccination coverage, vaccinations in Jerusalem have increased by 500% since September compared to the same period last year, and by 630% in Beit Shemesh.

In light of these figures, the first-dose vaccination coverage (for ages 1-6) against measles in Jerusalem rose from 77% to 84%, and in Beit Shemesh from 72% to 82.6%.

According to the U.S. CDC, international travelers planning to visit Israel in 2025 should be fully vaccinated against measles and polio.

In the USA, these vaccines are offered at travel clinics and pharmacies.

Oct 27, 2025 • 3:11 am CDT
Maps 2025

The Los Angeles County Department of Public Health (LACDPH) recently confirmed the first local death from the West Nile virus (WNV) in the 2025. The resident of the San Fernando Valley was hospitalized and died from a neurological illness caused by severe West Nile virus.

A total of 14 West Nile virus infections have been documented in Los Angeles County in 2025, excluding Long Beach and Pasadena. Half of the infected people live in the San Fernando Valley region.

Public Health reports West Nile virus cases every year, generally from June to November, as the virus is endemic in the region.

According to LACDPH, about 1 in 150 people will have severe WNV symptoms that may include high fever, stiff neck, muscle weakness, and sometimes rash. Symptoms usually appear 3 to 14 days after being infected.

West Nile virus is the most common mosquito-borne disease affecting residents of LA County, which has also reported locally acquired dengue cases in 2025.

"To the family and friends grieving the loss of a loved one due to West Nile virus, we extend our heartfelt condolences,” said Muntu Davis, MD, MPH, Los Angeles County Health Officer, in a press release on October 24, 2025.

“This tragic loss reminds us how dangerous mosquito-borne diseases like West Nile virus and dengue can be. Protect yourself and your neighbors by using insect repellent, getting rid of standing water where mosquitoes breed, and keeping window and door screens in good repair. Small actions like these can make a big difference in preventing illness.”

In collaboration with local vector control agencies, Public Health monitors the risk of WNV infection. It actively engages residents to provide information about reducing the risk by promoting protective measures against mosquitoes.

As of October 27, 2025, there is no WNV vaccine available in the USA.

Oct 25, 2025 • 9:38 am CDT
US CDC 2025

The World Health Organization (WHO) today announced that polio vaccine coverage in Europe is at its lowest level in several years, leaving more than 450,000 infants unprotected.

In 2024, polio vaccination rates in Europe decreased.

"Gaps in immunization coverage make children vulnerable and pose a health security risk to our region and beyond," stated Ihor Perehinets, MPH, the regional emergency director for WHO's European office, in a press release issued on October 24, 2025.

This WHO warning comes as new polio cases have been confirmed in Afghanistan and Papua New Guinea, according to the Global Polio Eradication Initiative.

In Afghanistan, two patients were infected with wild poliovirus type 1 (WPV1), with paralysis onset in early October, bringing the country's total WPV1 cases to nine for 2025.

Meanwhile, Papua New Guinea (PNG) reported two cases of circulating vaccine-derived poliovirus type 2 (cVDPV2) this week in Central and Enga provinces, with paralysis onset in August. So far this year, PNG has confirmed three cVDPV2 cases.

Furthermore, poliovirus type 2 has been detected through routine wastewater surveillance in 6 countries in the Region (Finland, Germany, Israel, Poland, Spain, and the United Kingdom) since September 2024.

WHO/Europe, together with other GPEI partners, continues to support national and local public health authorities in their investigations and monitoring of the situation, as well as in strengthening immunization programs and rapidly responding to detections of the virus to prevent it from spreading. 

To alert international travelers to their polio risk in 2025, the U.S. CDC has issued a Travel Health Notice listing 39 countries. The CDC advises travelers to be fully vaccinated before visiting these areas.

 

Oct 24, 2025 • 1:46 pm CDT
US CDC 2025

Since the Zika virus was first detected in the Americas in 2015, the Pan American Health Organization (PAHO) and the World Health Organization (WHO) have reported cases from 52 countries and territories in the region.

As of October 24, 2025, the PAHO Zika data dashboard indicates that there have been over 23,000 cases and four related fatalities in the Region of the Americas this year.

The current leaders are Brazil (21,762), Bolivia (1,012), and Argentina (849).

And in the Central America Region, Costa Rica, El Salvador, and Guatemala are the unfortunate leaders in reporting this mosquito-transmitted disease.

This PAHO data aligns with 2024, when 44,480 cases and two related fatalities were confirmed across all countries for the entire year.

Last year, Brazil reported about 90% of all cases.

In the Americas, one in four Zika-infected people may develop symptoms, but in those who are affected, the disease is usually mild, with symptoms lasting between 2 and 7 days. The clinical appearance is often similar to dengue or chikungunya.

According to the PAHO, Zika virus infection during pregnancy poses severe risks to the fetus, ranging from congenital Zika syndrome to microcephaly to milder neurodevelopmental issues.

From a severity perspective, there is scientific consensus that Zika is a cause of Guillain-Barré syndrome.

As of October 2025, the UK travel advisory says that since there is no vaccination or medication to prevent Zika infection, women should avoid becoming pregnant while traveling to at-risk countries such as those listed above, and for 2 months after their last possible Zika virus exposure.

Prevention involves reducing mosquito populations and avoiding bites, which occur mainly during the day, says the UK advisory.

In the future, a Zika vaccine candidate may be approved for human use.

Oct 24, 2025 • 5:51 am CDT
US CDC 2025

Since the first cases of Oropouche virus disease (OROV) were detected in Panama at the end of 2024 and the beginning of this year, a total of 613 confirmed cases have been reported across seven regions in Panama during 2025.

According to Panama's health ministry, OROV crossed the southern border from Colombia and is now found in Panamá Metro, Los Santos, Herrera, Panamá Norte, Veraguas, Panamá Oeste, Coclé, Darién, and Panamá Este (East Panama).

This disease is primarily spread by the bites of infected biting midges (small flies) and mosquitoes.

The Ministry of Health recommends that residents living in areas with active virus transmission use repellent, wear long-sleeved shirts and long pants, and install mosquito nets or wire mesh on doors and windows. They are also urged to avoid traveling to areas with active virus transmission.

Blas Armién, national head of Epidemiology at the Ministry of Health, explained in a media release on October 22, 2025, "Of the 15 health regions, at least seven have identified the circulation of OROV in the human population."

Armién added the most common symptoms of Oropouche include sudden onset of high fever, intense headache with photophobia, muscle and joint pain, and, in some cases, skin rashes (exanthemas).

In this regard, Armién warned that infection during the first trimester of pregnancy can cause genetic alterations in the fetus, such as hydrocephalus. He also emphasized the importance of attending prenatal checkups, as a case of vertical transmission (from mother to child) has been reported in Panama.

Regarding neurological disorders, he mentioned that cases of Guillain-Barré syndrome and flaccid paralysis may occur.

Because it presents symptoms similar to those of dengue, a specific diagnostic algorithm is used to distinguish the two diseases.

To alert international travelers of this health risk, the U.S. CDC reissued a Level 1 - Practice Usual Precautions, Travel Health Notice in September 2025. The CDC has included countries such as Brazil and Cuba in this warning. 

The CDC says, given the limited information on the risk of possible spread through sex, including the unknown of whether the virus may be present in vaginal fluid, travelers and their partners concerned about possible sexual transmission of Oropouche virus can consider using condoms or not having sex during travel and for 6 weeks after returning from travel.

As of late October 2025, no preventive vaccines targeting OROV are available.

Oct 23, 2025 • 2:49 pm CDT
Pixabay 2025

The Government of the Hong Kong SAR Center for Health Protection (CHP) of the Department of Health today published an update on chikungunya fever (CF) cases.

As of October 23, 2025, Hong Kong has recorded 43 confirmed, imported CF cases this year.

Among these, a patient recently passed away.

The CHP says severe symptoms and deaths caused by CF are extremely rare, with a mortality rate of less than one in 1,000, and the conditions of the other 42 patients are mild.

The occurrence of severe complications is mainly related to the patients' underlying health conditions. Elderly persons (particularly those aged 65 or above), young children (particularly infants under 1 year old), pregnant women, and persons with chronic illnesses (such as hypertension, diabetes, or heart disease) are at higher risk of developing complications after contracting CF and may require a more extended recovery period.

Therefore, members of the public (especially the abovementioned high-risk groups) are advised to seek medical advice promptly if they develop relevant symptoms, particularly a fever, sudden severe joint pain, and skin rash, after visiting areas affected by CF.

Since the beginning of 2025, and as of September 30, a total of 445,271 suspected and confirmed CF cases and 155 CF-related deaths have been reported in 40 countries/territories.

Cases have been reported in the Americas, Africa, Asia, and Europe. CF outbreaks currently occur in many countries worldwide.

From a disease prevention option, chikungunya vaccines have been approved in various countries, including the United States.

Oct 23, 2025 • 2:19 pm CDT
Maps 2025

The European Center for Disease Prevention and Control (ECDC) recently reported that 13 countries in Europe reported about 1,000 locally acquired human cases of West Nile Virus (WNV) infection with known place of infection.

These local WNV cases have been reported by Italy (714), Greece (91), Serbia, France, Romania, Spain, Hungary, Croatia, Albania, North Macedonia, Bulgaria, Kosovo, and Türkiye.

The ECDC says that in Europe, 63 WNV deaths have been reported in 2025.

And as of October 22, 2025, Germany was added to this unfortunate listing.

A locally acquired human case of WNV has been reported in Aschaffenburg, Bavaria.

This is only the second case ever reported in Bavaria, the first being a vet in 2018. Between 2019 and 2024, 4-35 locally acquired cases of WNV were reported in Germany, most from the eastern part of the country.

With thousands of international travelers arriving to attend Oktoberfest, visitors should take steps to prevent mosquito bites.

As of October 23, 2025, there are no WNV vaccines available to protect people from this mosquito-transmitted disease.

Oct 23, 2025 • 1:59 pm CDT
Maps 2025

the South Carolina Department of Public Health (DPH) recently confirmed it is actively responding to a measles outbreak in the Upstate region.

As of October 21, 2025, DPH is reporting 23 cases of measles since early July, centered around Spartanburg County, home to over 320,000 people.

To date, all confirmed measles cases have been in unvaccinated individuals.

DPH wrote in a press release, "There has been a rise in measles cases in the Upstate this year, with most concentrated in Spartanburg County."

"Some cases are travel-related exposures or close contacts of known cases. Other cases have no identified source, suggesting that measles is circulating in the community and could spread further."

"We have seen measles spread quickly in unvaccinated households here in South Carolina."

"We also know that it can spread quickly in unvaccinated communities based on outbreaks in other states."

In response to the ongoing measles outbreak, DPH has activated its Mobile Health Unit to offer measles-mumps-rubella vaccine to unvaccinated individuals at no cost. 

 

Oct 22, 2025 • 1:26 pm CDT
Google Maps 2025

The Costa Rica Ministry of Health (MINSA) today announced it has strengthened health control measures in the province of Bocas del Toro, after a case of yellow fever was confirmed in October 2025. 

The measures include the implementation of a sanitary checkpoint and the intensification of epidemiological surveillance at border crossings, especially in Costa Rica's Guabito area.

The MINSA health alert (DM-RM-5785-2025) was issued on October 17, 2025, after Costa Rican authorities confirmed two imported cases of yellow fever in women from the jungle region of Peru. 

One of them had a complete vaccination schedule and did not present symptoms, while the other, without immunization, did develop the disease. This patient was discharged from the hospital after showing favorable clinical progress.

In addition, the institution urged the population to eliminate mosquito breeding sites in their homes and to maintain preventive measures, especially those planning to travel to or from countries where the virus is circulating.

The Ministry of Health reiterated that anyone entering the country from endemic areas must present an international yellow fever vaccination certificate or, if not, receive the corresponding dose upon arrival. 

Furthermore, MINSA Regional Director Daryl Palmore reported that the process of obtaining new doses of the yellow fever vaccine has begun to ensure its availability in the province and protect communities along the border.

Since 2017, the U.S. Centers for Disease Control and Prevention (CDC) has expanded its yellow fever vaccine recommendations for certain travelers visiting at-risk zones. However, the CDC has not issed a Travel Health Notice regarding Costa Rica's recent yellow fever disclosures. 

In the USA, yellow fever vaccination services are commercailly offered at travel clinics and pharmacies in 2025.

Oct 21, 2025 • 4:46 am CDT
Pixabay 2025

A pertussis (whooping cough) outbreak has once again been reported in the Argentine Republic.

As of mid-October, data up to Epidemiological Week 41 confirm that the Argentine health ministry reported 333 cases of whooping cough in the country. The confirmed cases for the year are distributed across 17 jurisdictions.

The region with the highest number of cases is the Central Region, where 260 cases were reported, of which 167 correspond to the province of Buenos Aires and 50 to the Autonomous City of Buenos Aires.

The Southern Region follows, with 58 cases registered within the framework of the outbreak currently affecting the city of Ushuaia in Tierra del Fuego.

The highest cumulative incidence during the 2025 outbreak has been recorded in Tierra del Fuego, which is located in the southern area.

This number exceeds the confirmed cases reported for the same period in 2021, 2022, and 2023.

Given its high contagiousness, the Ministry of Health is currently working with provincial authorities to ensure timely care for people with acute respiratory illness symptoms and their close contacts, to limit the spread of the disease.

The Ministry says it is essential to keep in mind that vaccination is the primary prevention strategy and one of the most effective interventions for reducing morbidity and mortality in infants and other vulnerable groups.

Pertussis is included in Argentina's National Immunization Schedule.

As of October 21, 2025, the U.S. CDC states international travelers should check the vaccines and medicines list and visit their healthcare provider at least a month before visiting Argentina, a country with about 45 million residents, which is located in the southern area of South America.

Oct 20, 2025 • 1:15 pm CDT
US Dept of State October 20, 2025

Two United States agencies recently updated travel advisories focused on discouraging international travelers from visiting the Republic of Colombia this year.

From a health perspectovem the U.S. Centers of Disease Control and Prevention (CDC) published a Level 2 Travel Health Notice in September 2025, stating there is an increased number of  mosquiteo-transmitted yellow fever cases in Colombia.

According to a Facebook post, as of October 19, 2025, a total of 136 confirmed yellow fever cases (60 deaths), have been reported in Colombia during 2024/25. The majority of cases have been reported in Tolima Department with 116 cases and 45 deaths. 

The CDC has also included Colombia in its Level 1 dengue and measles notices in 2025.

The CDC advices everyone planning a visit to Colombia speak with a travel vaccine expert about their immuinzation options before departing abroad.

Seperately, the U.S Department of State has issued a Level 3, Reconsider travel to Colombia due to crime, terrorism, civil unrest, and kidnapping.

The State Department advices visitors to not visit Arauca, Cauca (excluding Popayán), and Norte de Santander departments due to crime and terrorism. And anywhere near the Colombia-Venezuela border region.

If you do visiting Colombia in 2025, the government suggests enrolling in the Smart Traveler Enrollment Program to receive digital messages from the U.S. Embassy in Bogota and make it easier to locate you in an emergency.